Esperion Therapeutics (NASDAQ: ESPR) stock surged about 12% in intraday trading Tuesday after the company reported better-than-expected Q1 financial results.
Esperion Therapeutics (ESPR) has delivered impressive first-quarter results, with revenues reaching $137.74 million, marking a 467% year-over-year increase and beating the consensus estimate of $84.51 million. The company also reported an EPS of $0.34, marking a significant turnaround from the EPS loss of $(0.79) reported a year ago and exceeding the consensus of $0.05.
A surge in U.S. net product revenue, reaching $24.8 million, primarily drove the revenue growth, reflecting a 46% year-over-year increase. Collaboration revenue soared to $113.0 million, compared to $7.3 million in the previous year, fueled by increased tablet sales to international partners and sales growth within partner territories, alongside a settlement-related milestone payment.
Sheldon Koenig, President and CEO of Esperion Therapeutics, expressed satisfaction with the company’s performance, stating,
“We posted retail prescription equivalent growth of 43% year-over-year, generated our highest level of revenue yet, and ended the quarter with a cash balance that positions us to capitalize on our new label and deliver long-term value growth.”
Operational Developments and Strategic Initiatives
In March, Esperion Therapeutics received FDA approval for broad new label expansions for its NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid and ezetimibe) Tablets, based on CLEAR Outcomes data. These expansions include indications for cardiovascular risk reduction and expanded LDL-C lowering in primary and secondary prevention patients.
During the quarter, the company launched new commercial initiatives to raise patient awareness of NEXLETOL and NEXLIZET’s expanded labels. This included expanding the sales force to 150 representatives in the U.S. and developing new promotional materials and tools to supplement salesforce efforts.
Furthermore, Esperion initiated the technology transfer process for NILEMDO and NUSTENDI tablet manufacturing to Daiichi Sankyo Europe, with completion expected in the second half of 2025.
As part of the amended partnership, the company authorized Daiichi Sankyo Europe to proceed with a triple formulation product commercialization comprising bempedoic acid, ezetimibe, and a statin, potentially extending the product’s lifecycle in Europe.
Esperion Therapeutics (NASDAQ: ESPR) Stock Movement
ESPR stock jumped 11.79% to close at $2.37 on Tuesday. Its value increased by 20.30% this week. Trading activity has witnessed 45,902,476 (45.90 million) shares changing hands, well above the average daily volume of 6.75 million.
